AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33297742 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI (Siemens)
Number of subjects: 34
Study 33297742 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 34
Study 35872955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) < 49 (high-risk group)
Number of subjects: 2661
Study 35872955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) ≥ 49 (low-risk group)
Number of subjects: 2661
Study 35872955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression model analysis
Number of subjects: 2661
Study 33074940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (group L)
Number of subjects: 114
Study 33074940 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (group M)
Number of subjects: 114
Study 33074940 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (group C)
Number of subjects: 114
Study 32623510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide nasal spray (BCQB) 90 μg per nostril, four times daily for 4 weeks
Number of subjects: 720
Study 32623510 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 720
Study 32623510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencycloquidium bromide nasal spray (BCQB)
Number of subjects: 720
Study 33359277 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors dispensed to patients with indication (77.0%)
Number of subjects: 28782
Study 33359277 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors dispensed to patients without indication (29.7%)
Number of subjects: 28782
Study 33359277 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with RAS inhibitors
Number of subjects: 28782
Study 33106049 — intervention group
Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI
Number of subjects: 109
Study 33106049 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 109
Study 33348273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sb‐PFOA
Number of subjects: 691
Study 33348273 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PFOA or n‐PFOA
Number of subjects: 691
Study 33348273 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PFOS, total PFOA, and Sb‐PFOA
Number of subjects: 691
Study 33348273 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA and Sb‐PFOA
Number of subjects: 691
Study 35525420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrono-nutritional and sleep hygiene intervention
Number of subjects: 103
Study 35525420 — intervention group
Group type: COMPARATOR
Intervention: Usual GDM care
Number of subjects: 103
Study 33221631 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone + FO
Number of subjects: 37
Study 33221631 — intervention group
Group type: COMPARATOR
Intervention: risperidone + placebo
Number of subjects: 37
Study 32729763 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally)
Number of subjects: 10
Study 32729763 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise plus placebo
Number of subjects: 10
Study 32729763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion for 20 minutes
Number of subjects: 10
Study 32729763 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 35680813 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO 300 IU/(kg·d) combined with glucocorticoid
Number of subjects: 34
Study 35680813 — intervention group
Group type: COMPARATOR
Intervention: rhTPO (15,000 IU/d) combined with glucocorticoid
Number of subjects: 34
Study 33259643 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein pre-meal (20 g)
Number of subjects: 24
Study 33259643 — intervention group
Group type: COMPARATOR
Intervention: Water pre-meal
Number of subjects: 24
Study 32690185 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation and resistance training (CR + RT)
Number of subjects: 27
Study 32690185 — intervention group
Group type: COMPARATOR
Intervention: Placebo and resistance training (PL + RT)
Number of subjects: 27
Study 35866327 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 50
Study 35866327 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study 34745566 — intervention group
Group type: EXPERIMENTAL
Intervention: oxytocin 2.5 IU
Number of subjects: 240
Study 34745566 — intervention group
Group type: EXPERIMENTAL
Intervention: carbetocin 100 microg
Number of subjects: 240
Study 32258162 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot strike pattern using minimalist shoes
Number of subjects: 30
Study 32258162 — intervention group
Group type: COMPARATOR
Intervention: Original strike pattern using minimalist shoes
Number of subjects: 30
Study 36321243 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted subcision combined with polycaprolactone-based dermal fillers
Number of subjects: 10
Study 32245569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 12.5 mg kg‐1 i.v. over 150 min
Number of subjects: 129
Study 32245569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 129
Study 36221170 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO strategy (focused must-have vaccination strategy)
Number of subjects: 0
Study 36221170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 34268883 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended 5-min rest preceding AOBP assessment
Number of subjects: 90
Study 34268883 — intervention group
Group type: COMPARATOR
Intervention: Partially attended resting office BP
Number of subjects: 90
Study 34268883 — intervention group
Group type: COMPARATOR
Intervention: Resting office BP (attended and partially attended)
Number of subjects: 90
Study 34268883 — intervention group
Group type: COMPARATOR
Intervention: Casual office BP
Number of subjects: 90
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 872
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 10 years)
Number of subjects: 872
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lymphocytic leukemia
Number of subjects: 872
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically photodamaged skin
Number of subjects: 872
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cutaneous squamous cell carcinoma
Number of subjects: 872
Study 32267479 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratinocyte carcinoma risk model
Number of subjects: 872
Study 35020542 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Eyhance IOL
Number of subjects: 50
Study 35020542 — intervention group
Group type: COMPARATOR
Intervention: RayOne IOL
Number of subjects: 50
Study 33300481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-variation training
Number of subjects: 16
Study 33300481 — intervention group
Group type: COMPARATOR
Intervention: Low-variation training
Number of subjects: 16
Study 33276378 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood polygenic risk score (PRS)
Number of subjects: 66963
Study 33276378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult polygenic risk score (PRS)
Number of subjects: 66963
Study 32005514 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 190
Study 32005514 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 190
Study 32005514 — intervention group
Group type: COMPARATOR
Intervention: Xenon vs Sevoflurane
Number of subjects: 190
Study 35869551 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door policy implemented in intervention wards for 12 months.
Number of subjects: 0
Study 35869551 — intervention group
Group type: COMPARATOR
Intervention: Control ward with facultative open doors.
Number of subjects: 0
Study 32734356 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index (IPI) monitoring group (IM)
Number of subjects: 147
Study 32734356 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring group (IM)
Number of subjects: 147
Study 32734356 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring group (SM)
Number of subjects: 147
Study 34741911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical decision-making reasoning scheme intervention
Number of subjects: 101
Study 34741911 — intervention group
Group type: COMPARATOR
Intervention: Standard general course (Control group)
Number of subjects: 101
Study 32469158 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Stem (SS)
Number of subjects: 75
Study 32469158 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stem (CS)
Number of subjects: 75
Study 33657970 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological music therapy (2 times/week, 60 min/session for 3 months)
Number of subjects: 40
Study 33657970 — intervention group
Group type: COMPARATOR
Intervention: Control group (BA group)
Number of subjects: 40
Study 33550668 — intervention group
Group type: COMPARATOR
Intervention: Good appetite
Number of subjects: 690
Study 32779626 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Stress Management Training
Number of subjects: 142
Study 32779626 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 142
Study 35851489 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733
Study 35851489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 33689732 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based multifaceted quality improvement interventions
Number of subjects: 10006
Study 33689732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 10006
Study 36259531 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirator
Number of subjects: 40
Study 36259531 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 40
Study 36259531 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 40
Study 36259531 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of mask types
Number of subjects: 40
Study 32909200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear colonoscopy surveillance (CCS)
Number of subjects: 1350
Study 32909200 — intervention group
Group type: COMPARATOR
Intervention: Routine colonoscopy surveillance (RCS)
Number of subjects: 1350
Study 32909200 — intervention group
Group type: EXPERIMENTAL
Intervention: First repeat examination (CCS)
Number of subjects: 1350
Study 32909200 — intervention group
Group type: EXPERIMENTAL
Intervention: Second repeat examination (CCS)
Number of subjects: 1350
Study 32909200 — intervention group
Group type: EXPERIMENTAL
Intervention: Third repeat examination (CCS)
Number of subjects: 1350
Study 32535812 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatinib (500 mg)
Number of subjects: 70
Study 32535812 — intervention group
Group type: COMPARATOR
Intervention: Selatinib (tablets)
Number of subjects: 70
Study 32535812 — intervention group
Group type: COMPARATOR
Intervention: Selatinib (suspension)
Number of subjects: 70
Study 32535812 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (tablets)
Number of subjects: 70
Study 34543432 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS (small-quantity lipid-based nutrient supplements)
Number of subjects: 2711
Study 32854664 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMS application
Number of subjects: 12
Study 35678594 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 maintenance therapy (S1-MT)
Number of subjects: 183
Study 36734446 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sedation supplemented by magnesium sulfate
Number of subjects: 80
Study 36734446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 80
Study 36734446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented by correction of hypomagnesemia
Number of subjects: 80
Study 36734446 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard sedation therapy with benzodiazepines)
Number of subjects: 80
Study 36734446 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (Dexmedetomidine + magnesium)
Number of subjects: 80
Study 32122618 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette vapor with nicotine
Number of subjects: 17
Study 32122618 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette vapor without nicotine
Number of subjects: 17
Study 34028656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy plus Amitriptyline
Number of subjects: 135
Study 34028656 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 135
Study 34666255 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lifestyle intervention (4 weeks)
Number of subjects: 156
Study 34666255 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year
Number of subjects: 156
Study 35074280 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors including coping and self-efficacy
Number of subjects: 80
Study 35074280 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping catastrophizing and self-efficacy
Number of subjects: 80
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: cRM
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVAI
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVAII
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: ANOVA
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: ANOVA-Change
Number of subjects: 0
Study 34303343 — intervention group
Group type: EXPERIMENTAL
Intervention: RM
Number of subjects: 0
Study 34303343 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34774725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D metabolites (25(OH)D, 25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3‐Epi‐D3)
Number of subjects: 277
Study 34774725 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 277
Study 34774725 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 277
Study 34774725 — intervention group
Group type: COMPARATOR
Intervention: Overweight and obese subjects
Number of subjects: 277
Study 33429812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education
Number of subjects: 0
Study 33429812 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32453393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU daily for 6 months)
Number of subjects: 69
Study 32453393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1000 mg daily for 6 months)
Number of subjects: 69
Study 32453393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 35241076 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Safe Childbirth Checklist (mSCC) with PRONTO® simulation training and quality improvement (QI) activities
Number of subjects: 21472
Study 35241076 — intervention group
Group type: COMPARATOR
Intervention: Control sites without the modified SCC and PRONTO/QI support
Number of subjects: 21472
Study 33484479 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic therapy (Lactobacillus fermentum CECT5716)
Number of subjects: 0
Study 33484479 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 35151143 — intervention group
Group type: COMPARATOR
Intervention: LMA Fastrach™
Number of subjects: 99
Study 35151143 — intervention group
Group type: EXPERIMENTAL
Intervention: iLTS-D™
Number of subjects: 99
Study 35151143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 99
Study 34472881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination about obsessive-compulsive symptoms
Number of subjects: 145
Study 34472881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination about mood
Number of subjects: 145
Study 34472881 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 145
Study 32769027 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 65)
Number of subjects: 126
Study 32769027 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (n = 61)
Number of subjects: 126
Study 32769027 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent therapeutic CPAP use in patients with baseline depression
Number of subjects: 126
Study 34602460 — intervention group
Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment (2 treatments/day for 30 min each for 6 days)
Number of subjects: 71
Study 34602460 — intervention group
Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment
Number of subjects: 71
Study 34602460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 71
Study 32701652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34
Study 32701652 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene‐related peptide
Number of subjects: 34
Study 32701652 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery
Number of subjects: 34
Study 32701652 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial temporal artery
Number of subjects: 34
Study 32224045 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease flare during tapering of DMARDs
Number of subjects: 0
Study 32224045 — intervention group
Group type: COMPARATOR
Intervention: Control (well-controlled RA without flare)
Number of subjects: 0
Study 34091567 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-Based Mastery Learning (SBML)
Number of subjects: 0
Study 34091567 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 0
Study 33150703 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cell (BMMSC) therapy plus rehabilitation therapy and risperidone
Number of subjects: 32
Study 33150703 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy and risperidone
Number of subjects: 32
Study 34139763 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based physical rehabilitation program (3 months of supervised exercise training followed by 9 months of self-managed exercise)
Number of subjects: 164
Study 34139763 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based physical rehabilitation program
Number of subjects: 164
Study 34139763 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 164
Study 36501070 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine anhydrous (BET) 6 g/day for 14 days
Number of subjects: 18
Study 36501070 — intervention group
Group type: COMPARATOR
Intervention: Cellulose placebo (PLA) 6 g/day for 14 days
Number of subjects: 18
Study 36501070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL; 70% 1RM)
Number of subjects: 18
Study 36501070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load Blood Flow Restriction (LL-BFR; 20% 1RM at 80% arterial occlusion pressure)
Number of subjects: 18
Study 33745627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (300 mg, 1.2%)
Number of subjects: 10
Study 33745627 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (microcrystalline cellulose)
Number of subjects: 10
Study 32233107 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks
Number of subjects: 305
Study 32233107 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks plus Bevacizumab 15 mg/kg i.v. every 3 weeks
Number of subjects: 305
Study 32233107 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg orally daily (4 weeks on, 2 weeks off)
Number of subjects: 305
Study 36031721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic microvascular invasion group, n = 146
Number of subjects: 311
Study 36031721 — intervention group
Group type: COMPARATOR
Intervention: No pathologic microvascular invasion group, n = 165
Number of subjects: 311
Study 36031721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model created in the training cohort
Number of subjects: 311
Study 36031721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model validated in the validation cohort
Number of subjects: 311
Study 36031721 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve analysis
Number of subjects: 311
Study 33091149 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 122
Study 33091149 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis + CHD
Number of subjects: 122
Study 33091149 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122
Study 33091149 — intervention group
Group type: COMPARATOR
Intervention: CHD
Number of subjects: 122
Study 33091149 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 122
Study 34780207 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly session frequency
Number of subjects: 1322
Study 34780207 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) group (attenuated session frequency)
Number of subjects: 1322
Study 33296526 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 152
Study 33296526 — intervention group
Group type: COMPARATOR
Intervention: Variceal Band Ligation (VBL)
Number of subjects: 152
Study 36283827 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2881078 (females: 1.0 mg; males: 2.0 mg)
Number of subjects: 97
Study 36283827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 33221392 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prior to stress
Number of subjects: 23
Study 33221392 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 32271053 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 108